Methyl 3-Cyanobenzoate

13531-48-1

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise t hat is market-oriented and realizes industrial development through R&D¶ innovation and technology transformation.

key word:

innovative Pharmaceutical

Category:

Related

Product Description

Integrity, innovation, cooperation, sharing, win-win

The company integrates multiple resources and strives to bui≈ld a large health industry finance platform company integrating pharmaceut®ical, intelligent medical, bio pharmaceutical R&D, industriaλl production and sales.

The chemical reactions involved in the existing productπs include Foucault reaction, nitration reaction, sulfonation reaction, hydrogenationε reaction, fluorination reaction, chlorination reaction, bro mination reaction, diazotization reaction, format reaction, etc.

Related products

Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) inhibitor developed by Merck$. In October 2006, Sitagliptin phosphate Januvia was approved by FDA as the first DPP4 inhibi♣tor for the treatment of type ⅱ diabetes mellitus. The characteristics of this drug are that it ∏can stimulate insulin secretion while reducing hunger without causing weight gain. Hy♦poglycemia and edema will not occur, and it is suitable for diabetic patients with poor blood glu cose control and frequent hypoglycemia.

Sumatriptan Succinate

Medication for migraine

Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-$oriented and realizes industrial development through R&D innovation and technology transformation.

Ketoprofen

The non-steroidal anti-inflammatory drug ketoprofen is one of the most important produ₽cts for the treatment of arthritis. It is well tolerated and has a low incidence of side effe©cts

Pranlukast

Pranlukast, developed by Ono, is one of the three major leukotriene receptor anta≠gonists. In clinical application, it has good therapeutic effect on atoπpic asthma and other types of bronchial asthma, and the market prospe↓ct is huge. In the major category of asthma drugs, leukotriene recep≈tor antagonists have the fastest growing market share.

Avanafil

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is maδrket-oriented and realizes industrial development through R&D innovation and technology$ transformation.

Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome. It is the second drug approved by FDA≈ for Alzheimer's disease in the United States. Its treatm"ent reaches the target dose and has low toxic and side effects. It has been widel♣y recognized by our medical community, and good tolerance is its biggest advantage. In Octo↓ber 1999, Donepezil was launched in China under the trade name "Aricept", which is the mai×n chemical drug against Alzheimer's disease. At present, CFD↑A has approved a number of domestic enterprises to produce donepezil preparations, the main d≥osage forms are tablets, capsules, dispersive tablets,← oral disintegrating tablets.

Almotriptan

Migraine medication for adolescents

Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Apixaba★n (Eliquis, Bristol-Myers Squibb/Pfizer), a direct oral factor Xa inhibitor, was$ approved for use in the 27 EU member states. The world's first drug approved to prevent veno↔us thromboembolism (VTE) in adult patients undergoing elective h¶ip or knee replacement. From June 2019 to June 2020, the annual sales™ of apixaban products overseas reached about $15.4 billion, with a year-on-yea↔r growth of nearly 32%, and the API consumption reached about 23,960 kg, wit®h a year-on-year growth of about 28%. Compared with its main competitor, Rivaroxa₹ban, the drug's annual overseas sales are about $4.5 billion higher.

Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that ↔is market-oriented and realizes industrial development through R&D innovation and λtechnology transformation.

Clofarabine

It is a nucleotide analogue developed by Bioenvision and manufactured bγy Genzyme. On December 29, 2004, it was approved by FDA for the treatment of refra↑ctory or relapsed acute lymphoblastic leukemia (AL•L) in children.

Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-orien←ted and realizes industrial development through R&D innovation and techno✘logy transformation.

Product Consulting

Our staff will contact you within 24 hours (working days). ♣If you need other services, E-mail: 2880705932@qq.com
Submit